Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024
Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024
Lipocine宣佈在2024年EASL大會上最新口頭介紹LPCN 1148第二階段研究的數據
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.
Presentation Details
| Title | Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial |
| Presenter: | Dr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University |
| Session Title: | Late Breaker |
| Session Date and Time: | Saturday, 8 June, 14:00 - 15:30 CEST |
| Presentation Time: | 15.15 CEST |
| Location | Gold Room |
| Abstract Number: | LP139 |
About LPCN 1148
Lipocine is currently evaluating LPCN 1148 comprising testosterone laurate ("TL") for the management of decompensated cirrhosis. The Company believes LPCN 1148 targets unmet needs for patients with cirrhosis including improvements in sarcopenia and quality of life, prevention or reduction in the occurrence of decompensation events such as HE, and improvement in post liver transplant outcomes, survival, and costs.